Literature DB >> 7954404

CDK4 amplification is an alternative mechanism to p16 gene homozygous deletion in glioma cell lines.

J He1, J R Allen, V P Collins, M J Allalunis-Turner, R Godbout, R S Day, C D James.   

Abstract

Recently, it has been shown that a gene encoding the cyclin-dependent kinase 4 inhibitory protein, p16, is frequently targeted for homozygous deletions in several types of tumor cell lines, including those established from malignant gliomas. Here we have examined 32 glioma cell lines for amplification-associated overexpression of the CDK4 gene as an alternative mechanism for abrogating the growth-regulatory effects of p16. Two of the cell lines revealed high-level expression of CDK4 in association with gene amplification, and this alteration was observed among the 10 cases having intact p16 genes. Consequently, 24 of 32 glioma cell lines revealed one of two alternative genetic alterations, each of which indicates that increased cdk4 kinase activity is important to glial tumor development.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7954404

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  55 in total

Review 1.  Cell cycle regulators: mechanisms and their role in aetiology, prognosis, and treatment of cancer.

Authors:  R J Michalides
Journal:  J Clin Pathol       Date:  1999-08       Impact factor: 3.411

2.  Pattern of retinoblastoma pathway inactivation dictates response to CDK4/6 inhibition in GBM.

Authors:  W Ruprecht Wiedemeyer; Ian F Dunn; Steven N Quayle; Jianhua Zhang; Milan G Chheda; Gavin P Dunn; Li Zhuang; Joseph Rosenbluh; Shujuan Chen; Yonghong Xiao; Geoffrey I Shapiro; William C Hahn; Lynda Chin
Journal:  Proc Natl Acad Sci U S A       Date:  2010-06-07       Impact factor: 11.205

3.  Genomic alterations in human glioma cell lines detected by restriction landmark genomic scanning.

Authors:  M Nakamura; N Konishi; S Tsunoda; Y Hiasa; T Tsuzuki; K Takemura; K Kobitsu; T Sakaki
Journal:  J Neurooncol       Date:  1997-09       Impact factor: 4.130

4.  Transgenic expression of cyclin-dependent kinase 4 results in epidermal hyperplasia, hypertrophy, and severe dermal fibrosis.

Authors:  P L Miliani de Marval; I B Gimenez-Conti; M LaCava; L A Martinez; C J Conti; M L Rodriguez-Puebla
Journal:  Am J Pathol       Date:  2001-07       Impact factor: 4.307

5.  Sense p16 and antisense uPAR bicistronic construct inhibits angiogenesis and induces glioma cell death.

Authors:  Narasimharao Nalabothula; Sajani S Lakka; Dzung H Dinh; Meena Gujrati; William C Olivero; Jasti S Rao
Journal:  Int J Oncol       Date:  2007-03       Impact factor: 5.650

6.  P16 deletion and mutation analysis in human brain tumors.

Authors:  F G Barker; P Chen; F Furman; K D Aldape; M S Edwards; M A Israel
Journal:  J Neurooncol       Date:  1997-01       Impact factor: 4.130

7.  Pharmacologic inhibition of cyclin-dependent kinases 4 and 6 arrests the growth of glioblastoma multiforme intracranial xenografts.

Authors:  Karine Michaud; David A Solomon; Eric Oermann; Jung-Sik Kim; Wei-Zhu Zhong; Michael D Prados; Tomoko Ozawa; C David James; Todd Waldman
Journal:  Cancer Res       Date:  2010-03-30       Impact factor: 12.701

8.  Tumor cell complementation groups based on myogenic potential: evidence for inactivation of loci required for basic helix-loop-helix protein activity.

Authors:  A N Gerber; S J Tapscott
Journal:  Mol Cell Biol       Date:  1996-07       Impact factor: 4.272

9.  Cdk4 deficiency inhibits skin tumor development but does not affect normal keratinocyte proliferation.

Authors:  Marcelo L Rodriguez-Puebla; Paula L Miliani de Marval; Margaret LaCava; David S Moons; Hiroaki Kiyokawa; Claudio J Conti
Journal:  Am J Pathol       Date:  2002-08       Impact factor: 4.307

Review 10.  Cyclin D1 and human neoplasia.

Authors:  R Donnellan; R Chetty
Journal:  Mol Pathol       Date:  1998-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.